Meg Tirrell Log In | Learn More Molly Ferguson for STAT How did every parent’s worst nightmare — the death of a child — spur the creation of an incentive system to turn making drugs for childhood cancer from a high-risk, low-reward gamble to a bet a company might make?Before Nancy Goodman’s son, Jacob, died in 2009, there were only a few, old drugs at hand to treat him. After he died, she asked why. Tags cancerdrug developmentpolicy Signal Podcast @megtirrell About the Authors Reprints What’s included? Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED By Luke Timmerman and Meg Tirrell Jan. 18, 2017 Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Co-host “The Readout LOUD,” CNBC senior health and science reporter GET STARTED What is it? Episode 20: The death of a child and a golden ticket for drug makers STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.